TY - JOUR
T1 - Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014
T2 - The impact of human papillomavirus vaccination
AU - Shing, Jaimie Z.
AU - Hull, Pamela C.
AU - Zhu, Yuwei
AU - Gargano, Julia W.
AU - Markowitz, Lauri E.
AU - Cleveland, Angela A.
AU - Pemmaraju, Manideepthi
AU - Park, Ina U.
AU - Whitney, Erin
AU - Mitchel, Edward F.
AU - Griffin, Marie R.
N1 - Publisher Copyright:
© 2019
PY - 2019/6
Y1 - 2019/6
N2 - Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.
AB - Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.
KW - Anogenital warts
KW - HPV vaccination
KW - Impact
KW - Trend
UR - http://www.scopus.com/inward/record.url?scp=85064315725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064315725&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2019.04.007
DO - 10.1016/j.pvr.2019.04.007
M3 - Article
C2 - 30980966
AN - SCOPUS:85064315725
VL - 7
SP - 141
EP - 149
JO - Papillomavirus Research
JF - Papillomavirus Research
ER -